|
|
 |
|
Viewing report
|
|
|
|
Alzheimer's Disease Market Forecast
Datamonitor, Nov 2011, Pages: 55
Valued at almost $6bn in the seven major markets in 2011 (US, Japan, France, Germany, Italy, Spain, and the UK), the Alzheimer’s disease drug market is forecast to experience double-digit growth to 2020. The catalysts for this include an aging population, earlier and improved diagnosis, and the introduction of immunotherapies that will be prescribed in addition to existing treatments.
Features and benefits
- Access Datamonitor’s patient-based Alzheimer’s disease market forecast in the seven major markets, with transparent methodology and clear assumptions.
- Evaluate a highly granular forecast with sales value and volume projections to 2020 at the country, class, product, and indication level.
- Understand Alzheimer’s disease market dynamics and which factors will lead to commercial success.
- Review the products Datamonitor forecasts to launch over the next ten years, and how each subsequent launch will shape the market.
Highlights
- The Alzheimer’s disease market in the seven major markets is set to more than double over the next 10 years, from $5.8bn in 2011 to $14.5bn in 2020. The catalysts for this growth include an increasingly elderly population, earlier and improved diagnosis, and the introduction of immunotherapies.
- Pfizer/Eisai’s Aricept (donepezil) is set to remain the highest-selling brand in 2011 with Forest/Lundbeck/Merz’s Namenda (memantine) close behind. However, the two drugs are following differing growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are being severely eroded by generic competition.
- Beta-amyloid immunotherapies such as bapineuzumab, solanezumab, and Gammagard have the potential to grow the market by $7.6bn. Datamonitor forecasts that around 600,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2020 in the seven major markets.
Your key questions answered
- What degree of commercial success does Datamonitor forecast for key pipeline drugs?
- What will the overall Alzheimer’s disease market dynamics be over the next 10 years?
- How will sales of the major drug classes in Alzheimer’s disease evolve during the forecast period?
- Which of the seven major markets provides the greatest opportunity for growth?
- Which Alzheimer’s disease indications are the most lucrative?
|
|
|
|
